SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (2765)10/22/2019 10:15:04 AM
From: Miljenko Zuanic  Respond to of 3557
 
Correct (my tipo) 3Q-2018.
Now that you mentioned, let me say that while Eylea 3Q-2018 was "flat" relative to 2Q/4Q (summer in EU), 3Q-2017 was strong. So, maybe there is no 'pattern" for Eylea as it is for Lucentis? Also, UK (due to Brexit uncertainty and EMA changes) probably did bit advance Eylea porches (as Bayer indicated in 2Q-2019, stronger UK Eylea sale).